# US 2008/0287432 A1 · Compounds and Compositions as Protein Kinase Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0287432 A1
- Document ID: US20080287432A1
- Status: Published application
- Kind: A1
- Application number: 12/063,550
- Filed: 2006-08-15
- Published: 2008-11-20
- Earliest claimed: 2005-08-16
- Assignees: Irm LLC; The Scripps Research Institute
- Inventors: Barun Okram; Pingda Ren; Nathanael S. Gray
- Web page: https://patentgrep.com/patent/US20080287432A1

## CPC

- C07D 471/14: Ortho-condensed systems
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/06: Antipsoriatics
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 495/14: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a novel class of compounds of formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the AbI, Bcr-AbI, Aurora-A, SGK, Tie-2, Trk-B, FGFR3, c-kit, b-RAF, c-RAF, DYRK2, Fms, Fyn and PDGFRalpha and PDGFR&bgr; kinases.

## Claims

### Claim 1

A compound of Formula I:
in which:
X1 is selected from CH and N;
Y is selected from S and NR5; wherein R5 is selected from hydrogen and C1-6alkyl;
Z is selected from C and S(O);
R1 is selected from hydrogen and C1-6alkyl;
R2 is selected from C6-12aryl and —NR3R4;
R3 is selected from hydrogen and C1-6alkyl;
R4 is —XR5; wherein X is selected from a bond, C1-6alkylene and C1-10heterarylene; wherein R5 is selected from C6-10aryl and C1-10heteroaryl;
wherein said aryl or heteroaryl of R5 is optionally substituted with 1 to 3 radicals independently selected from C1-6alkyl, halo-substituted-C1-6alkyl, C3-8heterocycloalkyl, —C(O)NR6R7 and —NR6C(O)R7; wherein R6 is selected from hydrogen and C1-6alkyl; and R7 is selected from C6-10aryl and C1-10heteroaryl;
wherein said aryl or heteroaryl of R7 is optionally substituted with 1 to 3 radicals independently selected from —R8 and —OR8; wherein R8 is selected from C1-6alkyl, halo-substituted-C1-6alkyl, C6-12aryl, C1-10heteroaryl and C3-8heterocycloalkyl-C0-4-alkyl; wherein said aryl, heteroaryl and heterocycloalkyl substituents of R8 are optionally substituted with C1-6alkyl;
or R3 and R4, together with the atoms to which R3 and R4 are attached, form C3-8heterocycloalkyl optionally substituted with —C(O)NR6R9; wherein R6 is selected from hydrogen and C1-6alkyl; and R9 is selected from C6-10aryl and C1-10heteroaryl; and the pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The compound of claim 1 of Formula Ia:
in which:
X1 is selected from CH and N;
Y is selected from S and NR5; wherein R5 is selected from hydrogen and C1-6alkyl;
n is selected from 0, 1 and 2;
R1 is selected from hydrogen and C1-6alkyl; and
R12 is selected from hydrogen, C1-6alkyl, halo-substituted-C1-6alkyl, C3-8heterocycloalkyl, —C(O)NR6R7 and —NR6C(O)R7; wherein R6 is selected from hydrogen and C1-6alkyl; and R7 is selected from C6-10aryl and C1-10heteroaryl;
wherein said aryl or heteroaryl of R7 is optionally substituted with 1 to 3 radicals independently selected from —R8 and —OR8; wherein R8 is selected from C1-6alkyl, halo-substituted-C1-6alkyl, C6-12aryl, C1-10heteroaryl and C3-8heterocycloalkyl-C0-4alkyl; wherein said aryl, heteroaryl and heterocycloalkyl substituents of R8 are optionally substituted with C1-6alkyl.

### Claim 3 (depends on 2)

The compound of claim 2 in which: X1 is selected from CH and N; Y is selected from S and N(CH3); and R1 is hydrogen.

### Claim 4 (depends on 3)

The compound of claim 3 in which R12 is hydrogen, methyl, —C(O)NHR7, —NHC(O)R7, —N(CH3)C(O)R7 and morpholino; wherein R7 is selected from phenyl and isoxazolyl; wherein said phenyl or oxazolyl of R7 is optionally substituted with 1 to 2 radicals selected from iso-butyl, trifluoromethyl, phenoxy, ethyl-piperazinyl-methyl, methylpiperazinyl-methyl, methyl-imidazolyl and morpholino-methyl.

### Claim 5 (depends on 1)

The compound of claim 1 selected from: 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid [3-(3-trifluoromethyl-phenylcarbamoyl)-phenyl]-amide; 1-Methyl-1,6-dihydro-1,5,6-triaza-as-indacene-2-carboxylic acid [3-(3-trifluoromethyl-benzoylamino)phenyl]-amide; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid (4-morpholin-4-yl-phenyl)-amide; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid phenylamide; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid 3-trifluoromethyl-benzylamide; Morpholin-4-yl-(6H-1-thia-5,6-diaza-as-indacen-2-yl)-methanone; 2-Benzenesulfonyl-1-methyl-1,6-dihydro-1,5,6-triaza-as-indacene; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid [3-(3-trifluoromethyl-benzoylamino)-phenyl]-amide; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid [3-(3-trifluoromethyl-phenylcarbamoyl)-phenyl]-amide; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid [2-methyl-5-(3-trifluoromethyl-benzoylamino)-phenyl]-amide; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid [2-methyl-5-(3-trifluoromethyl-phenylcarbamoyl)-phenyl]-amide; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid {2-methyl-5-[methyl-(3-trifluoromethyl-benzoyl)-amino]-phenyl}-amide; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid {5-[4-(4-ethyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenylcarbamoyl]-2-methyl-phenyl}-amide; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid {2-methyl-5-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-benzoylamino]-phenyl}-amide; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid [2-methyl-5-(3-morpholin-4-ylmethyl-5-trifluoromethyl-phenylcarbamoyl)-phenyl]-amide; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid {2-methyl-5-[4-(2-methyl-imidazol-1-yl)-3-trifluoromethyl-benzoylamino]-phenyl}-amide; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid {2-methyl-5-[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenylcarbamoyl]-phenyl}-amide; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid [5-(5-tert-butyl-isoxazol-3-ylcarbamoyl)-2-methyl-phenyl]-amide; 4-(6H-1-Thia-5,6-diaza-as-indacene-2-carbonyl)piperazine-1-carboxylic acid (4-phenoxy-phenyl)-amide; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid {1-[3-(3-trifluoromethyl-benzoylamino)-phenyl]-1H-imidazol-2-yl}-amide; 1-Methyl-1,6-dihydro-1,5,6-triaza-as-indacene-2-carboxylic acid [2-methyl-5-(3-trifluoromethyl-benzoylamino)-phenyl]-amide; 1-Methyl-1,6-dihydro-1,5,6-triaza-as-indacene-2-carboxylic acid [3-(3-trifluoromethyl-benzoylamino)-phenyl]-amide; 1-Methyl-1,6-dihydro-1,5,6-triaza-as-indacene-2-carboxylic acid [3-(3-trifluoromethyl-phenylcarbamoyl)-phenyl]-amide; 6H-1-Thia-5,6,7-triaza-as-indacene-2-carboxylic acid [3-(3-trifluoromethyl-benzoylamino)-phenyl]-amide; 6H-1-Thia-5,6,7-triaza-as-indacene-2-carboxylic acid [2-methyl-5-(3-trifluoromethyl-benzoylamino)-phenyl]-amide; 6H-1-Thia-5,6,7-triaza-as-indacene-2-carboxylic acid [2-methyl-5-(4-morpholin-4-ylmethyl-3-trifluoromethyl-phenylcarbamoyl)-phenyl]-amide; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid [3-methoxy-5-(3-trifluoromethyl-benzoylamino)-phenyl]-amide; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid [3-methoxy-5-(3-trifluoromethyl-phenylcarbamoyl)-phenyl]-amide; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid [3-methoxy-5-(4-morpholin-4-ylmethyl-3-trifluoromethyl-phenylcarbamoyl)-phenyl]-amide; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid {3-methoxy-5-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenylcarbamoyl]-phenyl}-amide; 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid {3-[4-(4-ethyl-piperazin-1-yl)-3-trifluoromethyl-phenylcarbamoyl]-5-methoxy-phenyl}-amide; and 6H-1-Thia-5,6-diaza-as-indacene-2-carboxylic acid [2-methyl-5-(5-trifluoromethyl-1H-benzoimidazol-2-yl)-phenyl]-amide.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable excipient.

### Claim 7 (depends on 1)

A method for treating a disease in an animal in which inhibition of kinase activity can prevent, inhibit or ameliorate the pathology and/or symptomology of the disease, which method comprises administering to the animal a therapeutically effective amount of a compound of claim 1.

### Claim 8 (depends on 7)

The method of claim 7 in which the kinase is selected from Abl, Bcr-Abl, Aurora-A, SGK, Tie-2, Trk-B, FGFR3, c-kit, b-RAF, c-RAF, DYRK2, Fms, Fyn and PDGFRα and PDGFRβ.

### Claim 9 (depends on 1)

The use of a compound of claim 1 in the manufacture of a medicament for treating a disease in an animal in which the kinase activity of Abl, Bcr-Abl, Aurora-A, SGK, Tie-2, Trk-B, FGFR3, c-kit, b-RAF, c-RAF, DYRK2, Fms, Fyn and/or PDGFRα and PDGFRβ contributes to the pathology and/or symptomology of the disease.
